Department of Chemoradiotherapy, Tangshan People's Hospital, Tangshan, China
Department of Radiation Oncology, Shandong Cancer Hospital, Shandong Academy of Medical Sciences, Jinan, China
Neoplasma. 2018;65(4):592-598. doi: 10.4149/neo_2018_170620N436.
The value of adjuvant chemotherapy in T2N0 gastric cancer (GC) remains controversial. The aim of this retrospective study is to define a high-risk subgroup of pathological T2N0 GC patients and examine the impact of adjuvant chemotherapy on overall survival (OS). A total of 225 patients underwent R0 resection for T2N0 gastric adenocarcinoma between 2002 and 2012 and 51/225 (22.7%) of these received adjuvant chemotherapy. Multivariate Cox regression identified tumor location in the Upper1/3 of the stomach (peast one of the independent risk factor listed above, and we found that adjuvant chemotherapy significantly improved OS for this subgroup.
辅助化疗在 T2N0 胃癌（GC）中的价值仍存在争议。本回顾性研究的目的是确定病理 T2N0 GC 患者的高危亚组，并探讨辅助化疗对总生存期（OS）的影响。2002 年至 2012 年间，共有 225 例 T2N0 胃腺癌患者接受了 RO 切除术，其中 51/225（22.7%）例患者接受了辅助化疗。多因素 Cox 回归分析确定了肿瘤位于胃上部 1/3（上 1/3 段）是上述独立危险因素之一，我们发现辅助化疗可显著改善该亚组的 OS。
